\uff5e \u5927\u624bCRO\u306f\u8a66\u9a13\u30c7\u30fc\u30bf\u3068\u30d7\u30ed\u30bb\u30b9\u3092\u7d71\u5408\u5316\u3057\u3001\u53ef\u8996\u5316\u306e\u5411\u4e0a\u3068\u8fc5\u901f\u5316\u3092\u5b9f\u73fe \uff5e<\/p>\n
<\/p>\n
2022\u5e7410\u670828\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
Veeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : Sebastian Bather\u3001\u4ee5\u4e0b Veeva) \u306f\u3001\u533b\u85ac\u54c1\u958b\u767a\u696d\u52d9\u53d7\u8a17\u6a5f\u95a2\uff08CRO\uff09\u306e40\u793e\u304cVeeva Vault CTMS<\/a><\/strong>\u3092\u9078\u629e\u3057\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u5411\u3051\u306e\u81e8\u5e8a\u8a66\u9a13\u3092\u8fc5\u901f\u5316\u3001\u52b9\u7387\u5316\u3057\u3066\u3044\u308b\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u4e2d\u306b\u306f\u30b0\u30ed\u30fc\u30d0\u30ebCRO\u5927\u624b6\u793e\u306e\u3046\u3061\u306e\uff14\u793e\u3067\u3042\u308b\u3001Labcorp Drug Development\u793e\u3001Parexel\u793e\u3001Thermo Fisher Scientific\u793ePPD\u81e8\u5e8a\u7814\u7a76\u4e8b\u696d\u90e8\u3001Syneos Health\u793e\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002\u5404\u793e\u306fVeeva Vault Clinical Suite<\/a><\/strong>\u306e\u4f7f\u7528\u7bc4\u56f2\u3092Vault eTMF<\/a><\/strong>\u304b\u3089Vault CTMS\u3078\u3068\u62e1\u5927\u3057\u3001\u30af\u30ea\u30cb\u30ab\u30eb\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u5358\u4e00\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u4e00\u5143\u5316\u3057\u3066\u3044\u307e\u3059\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n Vault CTMS\u306f\u88fd\u85ac\u4f01\u696d\u4e0a\u4f4d20\u793e\u306e\u3046\u30619\u793e\u3092\u542b\u3080120\u793e\u4ee5\u4e0a\u306e\u30b9\u30dd\u30f3\u30b5\u30fc\u304b\u3089\u3082\u9078\u3070\u308c\u3001\u696d\u754c\u3092\u727d\u5f15\u3059\u308b\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3068\u3057\u3066\u6025\u6210\u9577\u3057\u3066\u3044\u307e\u3059\u3002CRO\u306f\u3001Vault CTMS\u306b\u3088\u308a\u3055\u3089\u306b\u6a19\u6e96\u5316\u3092\u9032\u3081\u3066\u3044\u304f\u3053\u3068\u3067\u3001Veeva Vault\u3092\u9078\u3076\u30b9\u30dd\u30f3\u30b5\u30fc\u306b\u5bfe\u5fdc\u3057\u306a\u304c\u3089\u3001\u52b9\u7387\u5316\u3092\u76ee\u6307\u3057\u305f\u30b9\u30bf\u30c7\u30a3\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u5316\u3092\u5b9f\u73fe\u3067\u304d\u307e\u3059\u3002<\/p>\n Vault CTMS\u3067\u306f\u8a66\u9a13\u306e\u8a55\u4fa1\u6307\u6a19\u3092\u3082\u308c\u306a\u304f\u8868\u793a\u3067\u304d\u308b\u305f\u3081\u3001CRO\u304c\u8a66\u9a13\u306e\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u3092\u7ba1\u7406\u3057\u3084\u3059\u304f\u306a\u308a\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u306b\u5bfe\u3059\u308b\u900f\u660e\u6027\u3082\u5411\u4e0a\u3067\u304d\u307e\u3059\u3002Vault CTMS\u3092\u4f7f\u7528\u3059\u308b\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u306f\u4e00\u8cab\u6027\u306e\u3042\u308b\u696d\u754c\u6a19\u6e96\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3088\u308a\u3001\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u304c\u5bb9\u6613\u306b\u306a\u308a\u3001\u8a66\u9a13\u60c5\u5831\u3092\u5171\u6709\u3067\u304d\u308b\u305f\u3081\u3001\u8a66\u9a13\u30dd\u30fc\u30c8\u30d5\u30a9\u30ea\u30aa\u5168\u4f53\u3092\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0\u306b\u628a\u63e1\u3059\u308b\u3053\u3068\u304c\u53ef\u80fd\u3067\u3059\u3002<\/p>\n Veeva Vault CTMS\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bHenry Galio\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cVeeva Vault CTMS\u306f\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u53cc\u65b9\u306e\u9700\u8981\u306b\u5bfe\u5fdc\u3059\u308b\u3088\u3046\u958b\u767a\u3055\u308c\u305f\u3001\u521d\u306e\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3067\u3059\u3002Veeva\u88fd\u54c1\u3092\u6d3b\u7528\u3057\u3066\u81e8\u5e8a\u8a66\u9a13\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u3092\u9032\u3081\u308b\u4f01\u696d\u304c\u5897\u3048\u308b\u306b\u3064\u308c\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u304a\u3088\u3073\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306e\u9023\u643a\u304c\u5f37\u5316\u3055\u308c\u3001\u8a66\u9a13\u306e\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u8a55\u4fa1\u304c\u8fc5\u901f\u5316\u3057\u3001\u88ab\u9a13\u8005\u767b\u9332\u3092\u52a0\u901f\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n Vault CTMS\u306f\u3001eTMF\u3001CTMS\u3001\u652f\u6255\u3044\u3001\u81e8\u5e8a\u8a66\u9a13\u30b9\u30bf\u30fc\u30c8\u30a2\u30c3\u30d7\u3001\u8a66\u9a13\u30c8\u30ec\u30fc\u30cb\u30f3\u30b0\u306a\u3069\u306e\u696d\u52d9\u306b\u304a\u3051\u308b\u60c5\u5831\u3084\u30c9\u30ad\u30e5\u30e1\u30f3\u30c8\u306e\u5171\u6709\u3092\u652f\u63f4\u3057\u3001\u8a66\u9a13\u306e\u30e9\u30a4\u30d5\u30b5\u30a4\u30af\u30eb\u5168\u4f53\u3092\u901a\u3057\u3066\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u3068\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u5b9f\u73fe\u3059\u308bVeeva Vault Clinical Operations Suite<\/a><\/strong>\u306e\u4e00\u90e8\u3067\u3059\u3002<\/p>\n <\/p>\n \u3010<\/strong>Veeva Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward-looking Statements<\/strong>\u3011<\/strong> Veeva\u306f\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u533b\u85ac\u54c1\u958b\u767a\u696d\u52d9\u53d7\u8a17\u6a5f\u95a2\uff08CRO\uff09\u5927\u624b6\u793e\u306e\u3046\u3061\u306e\uff14\u793e\u3092\u542b\u308040\u793e\u304c\u3001Veeva Vault CTMS\u3092\u9078\u629e\u3057\u3066\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u5411\u3051\u306e\u81e8\u5e8a\u8a66\u9a13\u3092\u8fc5\u901f\u5316\u3001\u52b9\u7387\u5316\u200b\u3057\u3066\u3044\u308b\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n","protected":false},"author":131,"featured_media":47832,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-47830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47830"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=47830"}],"version-history":[{"count":4,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47830\/revisions"}],"predecessor-version":[{"id":47870,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47830\/revisions\/47870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media\/47832"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=47830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=47830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=47830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nVeeva Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u30671,100\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u3001\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066Veeva\u306f\u3001\u9867\u5ba2\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001veeva.com\/jp<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"